MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Association of Parkinson’s disease severity and cortical and subcortical cognitive markers

H. Duran-Meza, A.D. Santana-Vargas, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, G. Millan-Rosas, U. Jimenez-Correa, M. Lopez-Ruiz (Mexico City, Mexico)

Meeting: 2016 International Congress

Abstract Number: 883

Keywords: Cognitive dysfunction, Dementia, Scales

Session Information

Date: Tuesday, June 21, 2016

Session Title: Parkinson's disease: Pathophysiology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To assess cortical and subcortical dysfunction in several stages of Parkinson’s disease (PD) using the Parkinson’s disease-cognitive rating scale (PD-CRS).

Background: Cognitive impairment in PD is mainly associated to dopamine depletion in the fronto-striatal circuits (subcortical alterations), however cognitive impairment related to cortical areas and different neurotransmitters may be considered as a marker for risk of dementia. The Parkinson’s disease Cognitive Rating Scale (PD-CRS) provides information of cognitive deficits regarding to subcortical and cortical dysfunction. Cognitive impairment usually appears on early stages as a no-motor symptom and the severity can be explained by spatiotemporal progression of Lewy bodies inclusions, resulting in cognitive dysfunction decline and higher risk of dementia.

Methods: Forty four Parkinson’s disease patients and twelve healthy participants (CG) accomplished cognitive evaluation for cognitive impairment and dementia risk using PD-CRS.

Results: CG (n= 12; Mean age=59.5, SD 12.29; 8 women), PD patients (n=44 mean age 61, SD= 9.14, 20 women, 27 Hoehn & Yahr 1-2) one patient was discarded for incomplete data. No statistical differences were found in CG vs EP HY 1-2, differences were found regarding higher severity of PD HY 3-4 in total [F (2,52)=8.036, p=0.001], subcortical [F (2,52)=6.734, p=0.003], and cortical scores [F (2,52)=4.060, p=0.023]. Risk of dementia is associated to cortical subtest naming and copy of a clock. When comparing severity of PD HY1-2 vs HY3-4, lower scores were found only for naming subtest (p= 0.021). Cognitive decline appeared in total (p=0.003), subcortical (p=0.001), and cortical scores (p=0.012). Subcortical differences were found in attention (p=0.001), delayed verbal memory (p=0.014), and alternating fluency (p= 0.005).

Conclusions: Association of PD and cognitive impairment is easy identifiable in late stages of PD. Decline in specific areas may occur with progression of disease. In HY 3-4 stages, cortical and subcortical functioning account for cognitive impairment. For dementia risk only naming test appear to contribute for cortical impairment.

To cite this abstract in AMA style:

H. Duran-Meza, A.D. Santana-Vargas, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, G. Millan-Rosas, U. Jimenez-Correa, M. Lopez-Ruiz. Association of Parkinson’s disease severity and cortical and subcortical cognitive markers [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/association-of-parkinsons-disease-severity-and-cortical-and-subcortical-cognitive-markers/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/association-of-parkinsons-disease-severity-and-cortical-and-subcortical-cognitive-markers/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley